Published January 1, 2018 | Version v1
Journal article Open

Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation

  • 1. Ege Univ, Fac Pharm, Dept Pharmaceut Technol, Genclik Caddesi Ege Univ Kampusu, TR-35040 Izmir, Turkey
  • 2. Izmir Katip Celebi Univ, Fac Pharm, Dept Pharmaceut Technol, Izmir, Turkey
  • 3. Ege Univ, Fac Pharm, Dept Radiopharm, Izmir, Turkey
  • 4. Ege Univ, Fac Pharm, Dept Pharmacol, Izmir, Turkey
  • 5. Ege Univ, Fac Pharm, Dept Biochem, Izmir, Turkey
  • 6. Ege Univ, Fac Med, Dept Pathol, Izmir, Turkey

Description

Introduction: Bladder cancer is responsible for more than 130,000 deaths annually worldwide. Intravesical delivery of chemotherapeutic agents provides effective drug localization to the target area to reduce toxicity and increase efficacy. This study aimed to develop ail intravesical delivery system of gemcitabine HC1 (Gem-HCl) to provide a sustained-release profile, to prolong residence time, and to enhance its efficiency in the treatment of bladder cancer.

Files

bib-a266abef-09ee-4cd9-badf-547461412ac9.txt

Files (323 Bytes)

Name Size Download all
md5:e59255d8e67acaf30f7f3312f36cb4b3
323 Bytes Preview Download